ACT Genomics Statement

ACT Genomics Co. Limited, aleader in precision diagnostics and clinical testing, and mProbe Taiwan Inc., apioneer in proteomics technology for precision health, have signed a Memorandumof Understanding (MOU) to collaborate on advancing precision medicine acrossAsia. The agreement aims to combine the unique expertise of both companies toprovide cutting-edge diagnostic solutions to healthcare providers in theregion.

The next-generation oncology diagnostic powerhouse is formed in Asia, ACT Genomics and Sanomics offering total solutions to patients, medical professionals, pharmaceutical companies, and research institutes globally.